Your browser doesn't support javascript.
Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study.
Leke, Aminkeng Zawuo; Dolk, Helen; Loane, Maria; Casson, Karen; Nelen, Vera; Barisic, Ingeborg; Garne, Ester; Rissman, Anke; O'Mahony, Mary; Neville, Amanda J; Pierini, Anna; Bergman, Jorieke E H; Klungsøyr, Kari; Materna-Kiryluk, Anna; Bielenska, Anna Latos; Carbonell, Clara Cavero; Addor, Marie-Claude; Tucker, David.
  • Leke AZ; Centre for Maternal, Fetal and Infant Research, Institute for Nursing and Health Research, Ulster University, United Kingdom. Electronic address: az.leke@ulster.ac.uk.
  • Dolk H; Centre for Maternal, Fetal and Infant Research, Institute for Nursing and Health Research, Ulster University, United Kingdom.
  • Loane M; Centre for Maternal, Fetal and Infant Research, Institute for Nursing and Health Research, Ulster University, United Kingdom.
  • Casson K; Centre for Maternal, Fetal and Infant Research, Institute for Nursing and Health Research, Ulster University, United Kingdom.
  • Nelen V; Provinciaal Instituut voor Hygiëne, Antwerp, Belgium.
  • Barisic I; Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Croatia, Zagreb, Croatia.
  • Garne E; Paediatric Department Hospital, Lillebaelt Skovvangen, Kolding, Denmark.
  • Rissman A; Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University Magdeburg, Germany.
  • O'Mahony M; Medicine Department of Public Health, St Finbarr's Hospital Douglas Road, Cork, Ireland.
  • Neville AJ; IMER Registry (Emila Romagna Registry of Birth Defects), Center for Clinical and Epidemiological Research, University of Ferrara - Azienda Ospedaliero - Universitaria di Ferrara, Corso della Giovecca, Ferrara, Italy.
  • Pierini A; Tuscany Registry of Congenital Defects, CNR Institute of Clinical Physiology/Fondazione Toscana Gabriele Monasterio, Pisa, Italy.
  • Bergman JEH; Department of Medical Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Klungsøyr K; Medical Birth Registry of Norway, Kalfarveien, Bergen, Norway.
  • Materna-Kiryluk A; Polish Registry of Congenital Malformations, Department of Medical Genetics, Poznan University of Medical Sciences, Poznan, Poland.
  • Bielenska AL; Poznan University of Medical Sciences, Department of Medical Genetics, 8 Rokietnicka Street, 60-806, Poznan, Poland.
  • Carbonell CC; Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain.
  • Addor MC; Registre Vaudois des Malformations EUROCAT Department of Woman-Mother-Child, Maternité, Lausanne, Switzerland.
  • Tucker D; Congenital Anomaly Register & Information Service, Level 3 West Wing, Singleton Hospital, Sketty Lane, Swansea, United Kingdom.
Reprod Toxicol ; 100: 101-108, 2021 03.
Article in English | MEDLINE | ID: covidwho-1033759
ABSTRACT
This study investigated the risk of congenital heart defects (CHD) and other congenital anomalies (CA) associated with first trimester use of macrolide antibiotics (mainly erythromycin, spiramycin, clarithromycin and azithromycin) and lincosamides (clindamycin) using a case-malformed control design. Data included 145,936 babies with a CA diagnosis (livebirths, stillbirths and terminations of pregnancy for CA) from 15 population-based EUROCAT registries in 13 European countries, covering 9 million births 1995-2012. Cases were babies with CHD, anencephaly, orofacial clefts, genital and limb reduction anomalies associated with antibiotic exposure in the literature. Controls were babies with other CA or genetic conditions. Main outcomes were odds ratios adjusted (AOR) for maternal age and registry, with 95 % Confidence Intervals (95 %CI). Macrolide and lincosamide exposure was recorded for 307 and 28 cases, 72 and 4 non-genetic controls, 57 and 7 genetic controls, respectively. AOR for CHD was not significantly raised (AOR 0.94, 95 %CI 0.70-1.26 vs non-genetic controls; AOR 1.01, 95 %CI 0.73-1.41 vs genetic controls), nor significantly raised for any specific macrolide. The risk of atrioventricular septal defect was significantly raised with exposure to any macrolide (AOR 2.98; 95 %CI 1.48-6.01), erythromycin (AOR 3.68, 95 %CI 1.28-10.61), and azithromycin (AOR 4.50, 95 %CI 1.30-15.58). Erythromycin, clarithromycin, azithromycin, and clindamycin were associated with an increased risk of at least one other CA. Further research is needed on the risk of specific CA associated with macrolide and lincosamide use in the first trimester, particularly relevant for the potential use of azithromycin in the treatment of COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Abnormalities, Drug-Induced / Macrolides / Lincosamides / Anti-Bacterial Agents Type of study: Observational study / Prognostic study Limits: Female / Humans / Pregnancy Language: English Journal: Reprod Toxicol Journal subject: Embryology / Reproductive Medicine / Toxicology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Abnormalities, Drug-Induced / Macrolides / Lincosamides / Anti-Bacterial Agents Type of study: Observational study / Prognostic study Limits: Female / Humans / Pregnancy Language: English Journal: Reprod Toxicol Journal subject: Embryology / Reproductive Medicine / Toxicology Year: 2021 Document Type: Article